All Outputs (4)

Adult-onset testosterone deficiency: the usefulness of hormone replacement in reducing mortality in men with this common age-related condition (2024)
Journal Article
Mann, A., Strange, R. C., Hackett, G., König, C., & Ramachandran, S. (2024). Adult-onset testosterone deficiency: the usefulness of hormone replacement in reducing mortality in men with this common age-related condition. Exploration of Endocrine and Metabolic Diseases, 2024(1), 83-100. https://doi.org/10.37349/eemd.2024.00010

Adult-onset testosterone deficiency (TD) in men is diagnosed by the finding of low serum testosterone levels and recognised, associated symptoms. The condition has high prevalence in men over 50 years of age, particularly those with type 2 diabetes (... Read More about Adult-onset testosterone deficiency: the usefulness of hormone replacement in reducing mortality in men with this common age-related condition.

Testosterone therapy over 60 months improves aging male symptoms scores in all men with adult-onset testosterone deficiency (2024)
Journal Article
Haider, K. S., Zitzmann, M., Ramachandran, P., König, C. S., Hackett, G., Haider, A., …Ramachandran, S. (2024). Testosterone therapy over 60 months improves aging male symptoms scores in all men with adult-onset testosterone deficiency. The aging male : the official journal of the International Society for the Study of the Aging Male, 27(1), Article 2357548. https://doi.org/10.1080/13685538.2024.2357548

Objective
We evaluated change (Δ) in AMSS in men with adult-onset testosterone deficiency (TD) on/not on testosterone undecanoate (TU) by analysing a registry of men with adult-onset TD.

Methods
Analyses were performed using non-parametric stati... Read More about Testosterone therapy over 60 months improves aging male symptoms scores in all men with adult-onset testosterone deficiency.

Testosterone therapy reduces insulin resistance in men with adult‐onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open‐label phase (2024)
Journal Article
Tishova, Y., Kalinchenko, S., Mskhalaya, G., Hackett, G., Livingston, M., König, C., …Ramachandran, S. (2024). Testosterone therapy reduces insulin resistance in men with adult‐onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open‐label phase. Diabetes, Obesity and Metabolism, 26(6), 2147-2157. https://doi.org/10.1111/dom.15520

Aims
To describe changes in homeostasis model assessment of insulin resistance index (HOMA-IR) following testosterone therapy in men with hypogonadism and metabolic syndrome (MetS).

Materials and Methods
A randomized, placebo-controlled, double-... Read More about Testosterone therapy reduces insulin resistance in men with adult‐onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open‐label phase.

Testosterone Replacement Therapy: Effects on Blood Pressure in Hypogonadal Men (2024)
Journal Article
Hackett, G., Mann, A., Haider, A., Haider, K. S., Desnerck, P., König, C. S., …Ramachandran, S. (in press). Testosterone Replacement Therapy: Effects on Blood Pressure in Hypogonadal Men. The World Journal of Men's Health, 42, https://doi.org/10.5534/wjmh.230239

While testosterone therapy can improve the various pathologies associated with adult-onset testosterone deficiency (TD), Summary of Product Characteristics (SPC) of five testosterone preparations caution that treatment may be associated with hyperten... Read More about Testosterone Replacement Therapy: Effects on Blood Pressure in Hypogonadal Men.